Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioAmber Inc. BIOAQ

BioAmber Inc is an industrial biotechnology company producing renewable chemicals. The company's proprietary technology platform combines industrial biotechnology and chemical catalysis to convert bio-based feedstocks into renewable chemicals that are cost-competitive replacements for petroleum-derived chemicals used in a wide variety of everyday products including plastics, resins, paints, food additives and personal care products. BioAmber produces bio-succinic acid at a facility in Sarnia, On


OTCPK:BIOAQ - Post by User

Post by Rocky7777on Mar 21, 2018 9:25pm
136 Views
Post# 27758090

February 2018 Warrants

February 2018 Warrants"February 2018 Warrants
On February 9, 2018, we sold 15,969,166 Series A Units, with each Series A Unit consisting of one share of our common stock, one Series A common stock purchase warrant, or “Series A common warrant,” to purchase one share of our common stock, and one Series B common stock purchase warrant, or “Series B common warrant,” to purchase one share of our common stock and one Series C common stock purchase warrant, or “Series C common warrant,” to purchase that number of shares of our common stock as set forth therein (and the shares of common stock issuable from time to time upon exercise of these common warrants) to certain institutional investors in a registered direct offering. For investors whose purchase of Series A Units would have resulted in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock following the closing of the offering, we offered the opportunity to purchase, in lieu of Series A Units that have would otherwise resulted in ownership in excess of 4.99% of our outstanding common stock, 30,935,833 Series B Units. Each Series B Unit consists of one pre-funded common stock purchase warrant, or “pre-funded warrant,” to purchase one share of our common stock, one Series A common warrant, one Series B common warrant and one Series C common warrant (the Series A common warrants, Series B common warrants, Series C common warrants and pre-funded common warrants, collectively, the “February 2018 Common Warrants”).
320,787,498 shares of our common stock are issuable upon exercise of the February 2018 Common Warrants."

How did this add up to 321M?
<< Previous
Bullboard Posts
Next >>